In the last trading session, 13.22 million Akebia Therapeutics Inc (NASDAQ:AKBA) shares changed hands as the company’s beta touched 0.92. With the company’s per share price at $2.26 changed hands at $0.57 or 33.73% during last session, the market valuation stood at $533.88M. AKBA’s last price was a discount, traded about -9.73% off its 52-week high of $2.48. The share price had its 52-week low at $0.80, which suggests the last value was 64.6% up since then. When we look at Akebia Therapeutics Inc’s average trading volume, we note the 10-day average is 4.27 million shares, with the 3-month average coming to 2.38 million.
Analysts gave the Akebia Therapeutics Inc (AKBA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKBA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Akebia Therapeutics Inc’s EPS for the current quarter is expected to be -0.03.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA was in green as seen at the end of in last trading. With action 18.95%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 18.95%, with the 5-day performance at 18.95% in the green. However, in the 30-day time frame, Akebia Therapeutics Inc (NASDAQ:AKBA) is 7.11% up. Looking at the short shares, we see there were 14.88 million shares sold at short interest cover period of 7.64 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 65.23% from its current market value. According to analyst projections, AKBA’s forecast low is 6 with 7 as the target high. To hit the forecast high, the stock’s price needs a -209.73% plunge from its current level, while the stock would need to soar -165.49% for it to hit the projected low.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
Year-over-year growth is forecast to reach 20.99% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 44.38M. 3 analysts are of the opinion that Akebia Therapeutics Inc’s revenue for the current quarter will be 44.13M. The company’s revenue for the corresponding quarters a year ago was 32.61M and 43.65M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 36.09%. The estimates for the next quarter sales put growth at 1.12%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.58%. The 2025 estimates are for Akebia Therapeutics Inc earnings to increase by 35.35%.
AKBA Dividends
Akebia Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.45% of Akebia Therapeutics Inc shares while 28.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 30.25%. There are 28.90% institutions holding the Akebia Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.6786% of the shares, roughly 11.64 million AKBA shares worth $11.87 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.526% or 9.28 million shares worth $9.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 5.95 shares estimated at $13.44 million under it, the former controlled 2.72% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.62% of the shares, roughly 5.72 shares worth around $12.93 million.
